eISSN: 3023-6940
  • Home
  • Is it time to stage prostate cancer using molecular imaging?
E-SUBMISSION

Review

Is it time to stage prostate cancer using molecular imaging?


1 University of Health and Sciences, Ankara City Training and Research Hospital, Department of Urology, Ankara, Turkey

2 Gazi University, Faculty of Medicine, Department of Urology, Ankara, Turkey


DOI : 10.33719/yud.2022;17-2-1035767
New J Urol. 2022;17(2):109-115

ABSTRACT

Prostate cancer is one of the most common cancers in men. After the diagnosis is made, staging should be undertaken with imaging methods in order to plan the treatment and predict the prognosis. Parallel to technological developments in recent years, new imaging methods have entered into clinical use. Among these methods, prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging has come to the fore since it provides anatomical and functional imaging and has many advantages in tumor (T), nodal (N) and metastatic (M) staging. This review discusses the current status of the PSMA-PET method in prostate cancer staging.

Keywords: prostate cancer, staging, positron emission tomography


ABSTRACT

Prostate cancer is one of the most common cancers in men. After the diagnosis is made, staging should be undertaken with imaging methods in order to plan the treatment and predict the prognosis. Parallel to technological developments in recent years, new imaging methods have entered into clinical use. Among these methods, prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging has come to the fore since it provides anatomical and functional imaging and has many advantages in tumor (T), nodal (N) and metastatic (M) staging. This review discusses the current status of the PSMA-PET method in prostate cancer staging.

Keywords: prostate cancer, staging, positron emission tomography